Morgan Stanley
DMAC icon

Morgan Stanley’s DiaMedica Therapeutics DMAC Stock Holding History

Morgan Stanley’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$714K Sell
105,420
-442,190
-81% -$3.5M ﹤0.01% 5303
2025
Q4 		$4.36M Sell
547,610
-31,975
-6% -$239K ﹤0.01% 4288
2025
Q3 		$3.98M Buy
579,585
+339,109
+141% +$1.84M ﹤0.01% 4332
2025
Q2 		$938K Buy
240,476
+136,893
+132% +$534K ﹤0.01% 5127
2025
Q1 		$393K Buy
103,583
+16,154
+18% +$92.4K ﹤0.01% 5436
2024
Q4 		$475K Sell
87,429
-22,587
-21% -$107K ﹤0.01% 5433
2024
Q3 		$461K Buy
110,016
+23,816
+28% +$87.9K ﹤0.01% 5440
2024
Q2 		$254K Sell
86,200
-5,373
-6% -$14.7K ﹤0.01% 5575
2024
Q1 		$254K Sell
91,573
-150,417
-62% -$437K ﹤0.01% 5639
2023
Q4 		$687K Buy
241,990
+148,190
+158% +$367K ﹤0.01% 5480
2023
Q3 		$242K Buy
93,800
+36,700
+64% +$118K ﹤0.01% 5499
2023
Q2 		$247K Sell
57,100
-88
-0.2% -$214 ﹤0.01% 5550
2023
Q1 		$87.5K Buy
57,188
+1,987
+4% +$3.15K ﹤0.01% 6063
2022
Q4 		$87.2K Buy
55,201
+2,194
+4% +$2.96K ﹤0.01% 6043
2022
Q3 		$66K Buy
53,007
+5,207
+11% +$8.14K ﹤0.01% 6274
2022
Q2 		$96K Buy
47,800
+14,377
+43% +$33.5K ﹤0.01% 6296
2022
Q1 		$84K Buy
33,423
+9,523
+40% +$27K ﹤0.01% 6427
2021
Q4 		$89K Buy
23,900
+12,500
+110% +$49.1K ﹤0.01% 6504
2021
Q3 		$46K Sell
11,400
-12,227
-52% -$46.8K ﹤0.01% 6760
2021
Q2 		$105K Buy
23,627
+4,202
+22% +$34.5K ﹤0.01% 6338
2021
Q1 		$178K Sell
19,425
-1,235
-6% -$11.5K ﹤0.01% 5720
2020
Q4 		$210K Buy
20,660
+11,560
+127% +$63.2K ﹤0.01% 5563
2020
Q3 		$38K Buy
9,100
+3,300
+57% +$17.5K ﹤0.01% 5819
2020
Q2 		$41K Buy
+5,800
New +$25.9K ﹤0.01% 5741

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley's DMAC Position: Q1 2026 in Review

Morgan Stanley reduced its DiaMedica Therapeutics (DMAC) stake by 81% in Q1 2026, selling an estimated $3.5M and leaving 105,420 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #5303.

Morgan Stanley first reported a position in DMAC in Q2 2020 and has held it in 24 quarters since. The position peaked at $4.36M in Q4 2025. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Morgan Stanley held 105,420 shares of DiaMedica Therapeutics worth $714K as of Q1 2026.
  • Morgan Stanley sold 442,190 DiaMedica Therapeutics shares in Q1 2026, an estimated $3.5M.
  • DiaMedica Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5303 holding.
  • Morgan Stanley first reported a position in DiaMedica Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Morgan Stanley's DiaMedica Therapeutics position peaked at $4.36M in Q4 2025.
  • 99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.